Abstract
Objective: This study investigated improvements in quality of life associated with eight weeks of montelukast and/or intranasal steroid treatment for moderate to severe allergic rhinitis. Methods: A single-centre, prospective, randomised, double-blind, placebo-controlled study was carried out. Assessments were made using the Rhinoconjunctivitis Quality of Life Questionnaire and symptom scales. Results: A total of 128 patients (aged 13-51 years) were randomly assigned to one of two groups. In the montelukast group, patients were treated with montelukast tablets and fluticasone propionate nasal spray (n = 64). In the placebo group, treatment comprised a placebo and fluticasone propionate. The results showed significant improvements in symptom scores and quality of life scores for both groups after one month and two months of treatment, compared with baseline values; these improvements were significantly greater for the montelukast group compared with the placebo group. The mean number of loratadine tablets taken by each patient during the study period was only 0.73 for the montelukast group compared with 9 for the placebo group. Conclusion: The combination of montelukast tablets and fluticasone propionate nasal spray improved symptom control and overall quality of life for moderate to severe allergic rhinitis patients.
| Original language | English |
|---|---|
| Pages (from-to) | 242-248 |
| Number of pages | 7 |
| Journal | Journal of Laryngology and Otology |
| Volume | 128 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 12 Mar 2014 |
Fingerprint
Keywords
- Allergic Rhinitis
- Fluticasone Propionate
- Montelukast
- Quality Of Life
ASJC Scopus subject areas
- Otorhinolaryngology
- Medicine(all)
Cite this
Quality of life assessment in patients with moderate to severe allergic rhinitis treated with montelukast and/or intranasal steroids : A randomised, double-blind, placebo-controlled study. / Goh, Bee See; Ismail, M. I M; Husain, Salina.
In: Journal of Laryngology and Otology, Vol. 128, No. 3, 12.03.2014, p. 242-248.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Quality of life assessment in patients with moderate to severe allergic rhinitis treated with montelukast and/or intranasal steroids
T2 - A randomised, double-blind, placebo-controlled study
AU - Goh, Bee See
AU - Ismail, M. I M
AU - Husain, Salina
PY - 2014/3/12
Y1 - 2014/3/12
N2 - Objective: This study investigated improvements in quality of life associated with eight weeks of montelukast and/or intranasal steroid treatment for moderate to severe allergic rhinitis. Methods: A single-centre, prospective, randomised, double-blind, placebo-controlled study was carried out. Assessments were made using the Rhinoconjunctivitis Quality of Life Questionnaire and symptom scales. Results: A total of 128 patients (aged 13-51 years) were randomly assigned to one of two groups. In the montelukast group, patients were treated with montelukast tablets and fluticasone propionate nasal spray (n = 64). In the placebo group, treatment comprised a placebo and fluticasone propionate. The results showed significant improvements in symptom scores and quality of life scores for both groups after one month and two months of treatment, compared with baseline values; these improvements were significantly greater for the montelukast group compared with the placebo group. The mean number of loratadine tablets taken by each patient during the study period was only 0.73 for the montelukast group compared with 9 for the placebo group. Conclusion: The combination of montelukast tablets and fluticasone propionate nasal spray improved symptom control and overall quality of life for moderate to severe allergic rhinitis patients.
AB - Objective: This study investigated improvements in quality of life associated with eight weeks of montelukast and/or intranasal steroid treatment for moderate to severe allergic rhinitis. Methods: A single-centre, prospective, randomised, double-blind, placebo-controlled study was carried out. Assessments were made using the Rhinoconjunctivitis Quality of Life Questionnaire and symptom scales. Results: A total of 128 patients (aged 13-51 years) were randomly assigned to one of two groups. In the montelukast group, patients were treated with montelukast tablets and fluticasone propionate nasal spray (n = 64). In the placebo group, treatment comprised a placebo and fluticasone propionate. The results showed significant improvements in symptom scores and quality of life scores for both groups after one month and two months of treatment, compared with baseline values; these improvements were significantly greater for the montelukast group compared with the placebo group. The mean number of loratadine tablets taken by each patient during the study period was only 0.73 for the montelukast group compared with 9 for the placebo group. Conclusion: The combination of montelukast tablets and fluticasone propionate nasal spray improved symptom control and overall quality of life for moderate to severe allergic rhinitis patients.
KW - Allergic Rhinitis
KW - Fluticasone Propionate
KW - Montelukast
KW - Quality Of Life
UR - http://www.scopus.com/inward/record.url?scp=84922017358&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922017358&partnerID=8YFLogxK
U2 - 10.1017/S002221511400036X
DO - 10.1017/S002221511400036X
M3 - Article
C2 - 24618303
AN - SCOPUS:84922017358
VL - 128
SP - 242
EP - 248
JO - Journal of Laryngology and Otology
JF - Journal of Laryngology and Otology
SN - 0022-2151
IS - 3
ER -